Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cambium BioASX:CMB +4.88%28 EV-to-OCF is -2.92 as of Jul. 22, 2026. GuruFocus rates ASX:CMB with a GF Score™ of 28/100. The stock has 4 warning signs investors should review. Among 1,410 Biotechnology companies, Cambium Bio ranks worse than 52.84% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Cambium Bio's Enterprise Value is A$11.39 Mil.
Cambium Bio's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$-3.90 Mil. Therefore, Cambium Bio's EV-to-OCF for today is -2.92.
The historical rank and industry rank for Cambium Bio's EV-to-OCF or its related term are showing as below:
ASX:CMB'
s EV-to-OCF Range Over the Past 10 Years
Min: -2.78 Med: 0 Max: -2.78
Current: -2.78
During the past 12 years, the highest EV-to-OCF of Cambium Bio was -2.78. The lowest was -2.78. And the median was .
ASX:CMB's EV-to-OCF is ranked worse than 52.84% of 1410
companies
in the Biotechnology industry
Industry Median: -3.325
vs ASX:CMB: -2.78
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cambium Bio's PE Ratio (TTM) for today is calculated as:
Cambium Bio's share price for today is A$0.43.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cambium Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.186.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Cambium Bio EV-to-OCF Related Terms
Cambium Bio EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Cambium Bio's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Cambium Bio's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cambium Bio EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cambium Bio's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Cambium Bio's EV-to-OCF falls into.
Cambium Bio's current Enterprise Value is A$11.39 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cambium Bio's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$-3.90 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cambium Bio (ASX:CMB) has a EV-to-OCF of -2.92 as of Jul. 22, 2026. According to the industry distribution chart, Cambium Bio ranks #745 out of 1410 companies in the Biotechnology industry, placing it in the top 52.8%.
Is Cambium Bio's EV-to-OCF too high?
Cambium Bio's current EV-to-OCF is -2.92. Based on the distribution chart, Cambium Bio ranks #745 out of 1410 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Cambium Bio has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Cambium Bio's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cambium Bio ranks #745 out of 1410 companies for EV-to-OCF. This places Cambium Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Cambium Bio's current EV-to-OCF is -2.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cambium Bio stock overvalued right now?
Cambium Bio (ASX:CMB) has a current EV-to-OCF of -2.92. The current EV-to-OCF is -2.92. Cambium Bio's overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Cambium Bio (ASX:CMB), the current EV-to-OCF is -2.92 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate, Elate Ocular, is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.
28GF Score
Get the complete analysis for ASX:CMB
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CMB has been successfully added to your 
